Michael Thomas Henderson Sells 20,000 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson sold 20,000 shares of the stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $63.35, for a total transaction of $1,267,000.00. Following the sale, the chief executive officer directly owned 1,172,987 shares of the company’s stock, valued at approximately $74,308,726.45. The trade was a 1.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Michael Thomas Henderson also recently made the following trade(s):

• On Wednesday, January 14th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $81.11, for a total transaction of $1,622,200.00.
• On Wednesday, December 10th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $75.38, for a total transaction of $1,507,600.00.
• On Thursday, December 4th, Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $75.01, for a total transaction of $3,000,400.00.

Apogee Therapeutics Price Performance

NASDAQ APGE traded down $1.53 on Friday, hitting $67.78. The stock had a trading volume of 1,167,673 shares, compared to its average volume of 1,038,820. The business’s fifty day moving average price is $74.39 and its 200 day moving average price is $57.22. The stock has a market cap of $4.63 billion, a price-to-earnings ratio of -15.47 and a beta of 1.42. Apogee Therapeutics Inc. has a 52-week low of $26.20 and a 52-week high of $84.56.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.11) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.03. As a group, sell-side analysts anticipate that Apogee Therapeutics Inc. will post -3.09 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Apogee Therapeutics by 2.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock worth $921,000 after purchasing an additional 694 shares during the period. Millennium Management LLC boosted its stake in shares of Apogee Therapeutics by 100.0% in the first quarter. Millennium Management LLC now owns 260,335 shares of the company’s stock worth $9,726,000 after buying an additional 130,164 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in Apogee Therapeutics during the second quarter worth about $218,000. AlphaQuest LLC raised its position in Apogee Therapeutics by 344.6% during the second quarter. AlphaQuest LLC now owns 5,073 shares of the company’s stock valued at $220,000 after acquiring an additional 3,932 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in Apogee Therapeutics by 99.2% in the second quarter. Nisa Investment Advisors LLC now owns 769 shares of the company’s stock valued at $33,000 after acquiring an additional 383 shares during the period. 79.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. BTIG Research set a $137.00 price target on Apogee Therapeutics in a research note on Tuesday, January 6th. Stifel Nicolaus set a $133.00 target price on shares of Apogee Therapeutics in a research report on Tuesday, January 6th. Royal Bank Of Canada cut shares of Apogee Therapeutics from an “outperform” rating to a “sector perform” rating and raised their price target for the stock from $70.00 to $83.00 in a report on Thursday, January 22nd. Wolfe Research started coverage on shares of Apogee Therapeutics in a report on Wednesday, January 7th. They set a “peer perform” rating on the stock. Finally, Stephens initiated coverage on Apogee Therapeutics in a research note on Tuesday, December 16th. They issued an “overweight” rating and a $95.00 target price for the company. Three research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Apogee Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $104.58.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor ROR?t, a master regulator of T cell-driven inflammatory pathways. By modulating ROR?t activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral ROR?t inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.